Supplement S3: Supplementary Table: Concomitant Therapy – Full Analysis Set (FAS)

Concomitant Therapy	Randomised Treatment			
	PLASMA + SOC	SOC	Total	P-value
Total Number of Patients	320	163	483	
Specific Treatment for Covid-19 Used	130/320 (40.6%)	74/163 (45.4%)	204/483 (42.2%)	0.331
Chloroquine	0/320 (0.0%)	0/163 (0.0%)	0/483 (0.0%)	
Hydroxychloroquine	4/320 (1.3%)	3/163 (1.8%)	7/483 (1.4%)	0.693
Favipiravir	0/320 (0.0%)	0/163 (0.0%)	0/483 (0.0%)	
Remdesivir	46/319 (14.4%)	25/160 (15.6%)	71/479 (14.8%)	0.785
Tocilizumab	1/320 (0.3%)	2/163 (1.2%)	3/483 (0.6%)	0.264
Lopinavir/Ritonavir	1/320 (0.3%)	1/163 (0.6%)	2/483 (0.4%)	1.000
Other	78/320 (24.4%)	46/163 (28.2%)	124/483 (25.7%)	0.379
Other Antiviral Drugs	18/320 (5.6%)	8/163 (4.9%)	26/483 (5.4%)	0.833
Antibiotics	174/320 (54.4%)	94/163 (57.7%)	268/483 (55.5%)	0.500
Antifungal Treatment	30/320 (9.4%)	15/163 (9.2%)	45/483 (9.3%)	1.000
Systemic Corticosteroids	208/320 (65.0%)	112/162 (69.1%)	320/482 (66.4%)	0.414
Hydrocortisone	0/320 (0.0%)	1/162 (0.6%)	1/482 (0.2%)	0.336
Methylprednisolone	35/320 (10.9%)	25/162 (15.4%)	60/482 (12.5%)	0.188
Prednisolone	3/320 (0.9%)	0/162 (0.0%)	3/482 (0.6%)	0.554
Dexamethasone	179/320 (55.9%)	88/162 (54.3%)	267/482 (55.4%)	0.771
Other	1/320 (0.3%)	2/162 (1.2%)	3/482 (0.6%)	0.262
Anticoagulation	306/319 (95.9%)	153/160 (95.6%)	459/479 (95.8%)	1.000

Results are presented as n/N (%) whereby N=total number of patients with data available, n=number of patients with medication during hospital stay up to Day 30 and %=n*100/N. Differences between randomised groups were assessed using Fisher's exact test.